These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1222 related items for PubMed ID: 17320673

  • 1. Long-term prostate cancer control using palladium-103 brachytherapy and external beam radiotherapy in patients with a high likelihood of extracapsular cancer extension.
    Dattoli M, Wallner K, True L, Cash J, Sorace R.
    Urology; 2007 Feb; 69(2):334-7. PubMed ID: 17320673
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Long-term outcomes after treatment with external beam radiation therapy and palladium 103 for patients with higher risk prostate carcinoma: influence of prostatic acid phosphatase.
    Dattoli M, Wallner K, True L, Cash J, Sorace R.
    Cancer; 2003 Feb 15; 97(4):979-83. PubMed ID: 12569596
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. 20 Gy versus 44 Gy supplemental beam radiation with Pd-103 prostate brachytherapy: preliminary biochemical outcomes from a prospective randomized multi-center trial.
    Wallner K, Merrick G, True L, Sherertz T, Sutlief S, Cavanagh W, Butler W.
    Radiother Oncol; 2005 Jun 15; 75(3):307-10. PubMed ID: 16086912
    [Abstract] [Full Text] [Related]

  • 6. Prostatic acid phosphatase adversely affects cause-specific survival in patients with intermediate to high-risk prostate cancer treated with brachytherapy.
    Fang LC, Dattoli M, Taira A, True L, Sorace R, Wallner K.
    Urology; 2008 Jan 15; 71(1):146-50. PubMed ID: 18242384
    [Abstract] [Full Text] [Related]

  • 7. Influence of body mass index on biochemical outcome after permanent prostate brachytherapy.
    Merrick GS, Butler WM, Wallner KE, Galbreath RW, Allen Z, Lief JH, Adamovich E.
    Urology; 2005 Jan 15; 65(1):95-100. PubMed ID: 15667872
    [Abstract] [Full Text] [Related]

  • 8. Impact of supplemental external beam radiotherapy and/or androgen deprivation therapy on biochemical outcome after permanent prostate brachytherapy.
    Merrick GS, Butler WM, Wallner KE, Galbreath RW, Lief JH, Allen Z, Adamovich E.
    Int J Radiat Oncol Biol Phys; 2005 Jan 01; 61(1):32-43. PubMed ID: 15629591
    [Abstract] [Full Text] [Related]

  • 9. Radiation dose predicts for biochemical control in intermediate-risk prostate cancer patients treated with low-dose-rate brachytherapy.
    Ho AY, Burri RJ, Cesaretti JA, Stone NN, Stock RG.
    Int J Radiat Oncol Biol Phys; 2009 Sep 01; 75(1):16-22. PubMed ID: 19289266
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Conformal high dose rate iridium-192 boost brachytherapy in locally advanced prostate cancer: superior prostate-specific antigen response compared with external beam treatment.
    Stromberg JS, Martinez AA, Horwitz EM, Gustafson GS, Gonzalez JA, Spencer WF, Brabbins DS, Dmuchowski CF, Hollander JB, Vicini FA.
    Cancer J Sci Am; 1997 Sep 01; 3(6):346-52. PubMed ID: 9403047
    [Abstract] [Full Text] [Related]

  • 15. Tumor control outcomes of patients treated with trimodality therapy for locally advanced prostate cancer.
    Copp H, Bissonette EA, Theodorescu D.
    Urology; 2005 Jun 01; 65(6):1146-51. PubMed ID: 15922433
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Monotherapeutic brachytherapy for clinically organ-confined prostate cancer.
    Merrick GS, Butler WM, Wallner KE, Galbreath RW, Adamovich E.
    W V Med J; 2005 Jun 01; 101(4):168-71. PubMed ID: 16296198
    [Abstract] [Full Text] [Related]

  • 18. Clinical results of combined treatment conformal high-dose-rate iridium-192 brachytherapy and external beam radiotherapy using staging lymphadenectomy for localized prostate cancer.
    Hiratsuka J, Jo Y, Yoshida K, Nagase N, Fujisawa M, Imajo Y.
    Int J Radiat Oncol Biol Phys; 2004 Jul 01; 59(3):684-90. PubMed ID: 15183471
    [Abstract] [Full Text] [Related]

  • 19. Risk profiles to predict PSA relapse-free survival for patients undergoing permanent prostate brachytherapy.
    Potters L, Cha C, Oshinsky G, Venkatraman E, Zelefsky M, Leibel S.
    Cancer J Sci Am; 1999 Jul 01; 5(5):301-6. PubMed ID: 10526671
    [Abstract] [Full Text] [Related]

  • 20. Three-year results of treatment for prostate cancer with low-dose rate temporary iridium-192 brachytherapy.
    Momma T, Saito S, Toya K, Yorozu A, Dokiya T, Murai M.
    Int J Urol; 2006 Mar 01; 13(3):218-23. PubMed ID: 16643612
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 62.